The present invention relates to * combinations of: component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof； ¢ component B : one or more substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]-triazin-4-amine compounds of general formula (B), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof； ¢ in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially. dependently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route； * use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer； * a kit comprising such a combination； * use of biomarkers which is the loss of tumor suppressor PTEN or FBXW7, for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based dosage to increase sensitivity and/or to overcome resistance； * a method of determining the loss of tumor suppressor PTEN or FBXW7； and a method for determining perturbations in PIK3CA, PIK3CB, PIK3CD, PIK3CG, PI K3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 and/or FGFR4.La presente invención se refiere a: * combinaciones de: componente A: uno o más compuestos de 2,3-dihidroimidazo[1,2-c]qui nazolina de fórmula general (A1) o (A2), o una sal, solvato, hidrato o estereoisómero fisiológicamente aceptable de los mismos； componente B: uno o más compuestos de 5-(1-benzotiofen-2-il)pirrolo[2,l-f][1,2,4]-triazin-4-amina sustituida de fórmula general (B), o una sal, solvato, hidrato o estereoisómero fisiológicamente aceptable de los mismos； en las cuales opcionalmente algunos o todos los componentes están en forma de una formulación farmacéutica la cual está lista para su util
